Valeriu Gheorghita sends a message with a strong warning for Romanians all over the country in this period when the Coronavirus pandemic is not over yet, and he talks about the cases of myocarditis that have been detected so far following vaccination.
Valeriu Gheorghita talks below about what they mean, but also what kind of evolution the patients who were detected with this reaction had after vaccination with the Pfizer BioNTech serum, the military doctor asking people to carefully analyze the information vis-a- dream about this problem.
"What we will do in the next period is to communicate more intensively on this topic, with a preponderance on the young population, including children, precisely to provide sufficient information to parents, related to the safety profile of vaccines, effectiveness, efficiency, the direct and indirect benefits, but also of this particular issue really related to the risk of myocarditis.
What is myocarditis? In short, it is an inflammation of the heart muscle, which is not specific to the vaccination against COVID-19, it is found as a potential adverse reaction to other types of vaccines and is commonly caused by several infectious agents both viral, bacterial, parasites, fungi etc. So it has a multiple cause.
In particular, for vaccines against COVID-19, with messenger RNA based vaccines, it has been observed that in people under 30 years of age, so in general young people and especially male people, there is a slightly higher frequency than found in the general population, than the frequency found in the general population, after dose 2 of the vaccination schedule, generally the time of onset is about two to three days after dose 2, but there is generally surveillance up to 28 of days.
But most reported cases were in the first seven days after the second dose. The evolution was easy in all cases, in the sense that the duration of hospitalization was two-three to four days, comparatively there are more and more scientific data already available and published and which were also the basis of performing a risk-benefit ratio when the US Food and Drug Administration authorized the vaccine from the company BioNTech/Pfizer, in the sense in which the evolution of myocarditis after vaccination was compared with the evolution of myocarditis from COVID and the evolution of classic myocarditis."
